TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26210120

Group type: EXPERIMENTAL
Intervention: Non-operative caries treatment programme (NOCTP)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Topical fluoride applications (IPFA)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (standard prevention)
Number of subjects: 230
Study: 24095892

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: GlideScope Videolaryngoscopy (GVL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GlideScope Groove (GG)
Number of subjects: 34
Study: 21522073

Group type: EXPERIMENTAL
Intervention: Speed, Agility, Quickness (SAQ) training method
Number of subjects: 100
Study: 18205978

Group type: EXPERIMENTAL
Intervention: Methadone (Meth)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Buprenorphine (Bup)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Both Meth and Bup
Number of subjects: 140
Study: 16861095

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1,500 mg IV infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Levetiracetam 500 mg oral tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1,500 mg IV infusion (multiple doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (multiple doses)
Number of subjects: 18
Study: 12646326

Group type: EXPERIMENTAL
Intervention: Nicotine Maintenance (21 mg transdermal nicotine for 8 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard Treatment (tapered dosing regimen)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nicotine Maintenance
Number of subjects: 55
Study: 10844068

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 0
Study: 9412274

Group type: COMPARATOR
Intervention: Intravenous PCA (PCA-i.v.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural PCA (PCA-PDK)
Number of subjects: 40
Study: 8449067

Group type: COMPARATOR
Intervention: Bambuterol 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bambuterol 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bambuterol 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 3994163

Group type: EXPERIMENTAL
Intervention: 0.25 ppm sulfur dioxide in filtered air
Number of subjects: 19

Group type: COMPARATOR
Intervention: Filtered air alone
Number of subjects: 19
Study: 30099726

Group type: EXPERIMENTAL
Intervention: 8-week stress management intervention program (progressive muscle relaxation, diaphragmatic breathing, guided imagery, cognitive restructuring)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 8-week stress management intervention program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 26874892

Group type: EXPERIMENTAL
Intervention: Self-directed exercise intervention
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Self-directed nutrition intervention
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (≥2 hours)
Number of subjects: 312
Study: 24925584

Group type: EXPERIMENTAL
Intervention: Novolin® 30R (initial dose 0.5 IU/kg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Lantus® combined with acarbose (Glucobay®) (initial dose 0.2 IU/kg and 50 mg acarbose)
Number of subjects: 188
Study: 23684862

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21966941

Group type: COMPARATOR
Intervention: TACE alone (group 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MWA after TACE (group 2)
Number of subjects: 34
Study: 18436050

Group type: EXPERIMENTAL
Intervention: Initial calls to ED referral numbers
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Successful appointment attempts
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Hold time for callers
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Total telephone time for successful appointments
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Number of calls to reach appointment staff
Number of subjects: 603
Study: 16897026

Group type: EXPERIMENTAL
Intervention: Psychosocial quality of care by physicians
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active integration in treatment decisions
Number of subjects: 90
Study: 12534411

Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg b.d.) + Amoxicillin (750 mg b.d.) + Clarithromycin (400 mg b.d.)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.d.) + Amoxicillin (750 mg b.d.) + Clarithromycin (400 mg b.d.)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Clarithromycin-sensitive strains
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant strains
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Extensive metabolizers in RAC group
Number of subjects: 187

Group type: COMPARATOR
Intervention: Extensive metabolizers in LAC group
Number of subjects: 187
Study: 10497402

Group type: EXPERIMENTAL
Intervention: Step‐by‐step pharmacologic therapy including bronchodilators (beta 2‐agonists, anticholinergic agents), theophylline, and oral corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 8762348

Group type: EXPERIMENTAL
Intervention: Contaminated water consumption
Number of subjects: 3861
Study: 1849810

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg single oral dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 to 40 mg twice daily for 4 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Serotonin 1 ng/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Serotonin highest dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methoxamine
Number of subjects: 8
Study: 7000631

Group type: EXPERIMENTAL
Intervention: PGE2 (1 mg four times daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PGE2 (1 mg four times daily) with ASA (600 mg four times daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: ASA (600 mg four times daily)
Number of subjects: 27
Study: 31152605

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg every 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study: 28067718

Group type: EXPERIMENTAL
Intervention: DTaP-IPV//Hib booster vaccine administered concomitantly with CYD-TDV
Number of subjects: 732

Group type: COMPARATOR
Intervention: CYD-TDV administered as a 3-dose schedule
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Safety assessment of both vaccines
Number of subjects: 732
Study: 25886748

Group type: EXPERIMENTAL
Intervention: 50% xenon as an adjuvant to sevoflurane anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 40
Study: 23539078

Group type: EXPERIMENTAL
Intervention: Different devices for shoulder extensions at xiphoid process depth
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Shoulder extensions at xiphoid process depth
Number of subjects: 24

Group type: COMPARATOR
Intervention: Shoulder extensions at clavicle depth
Number of subjects: 24
Study: 21276644

Group type: EXPERIMENTAL
Intervention: High calcium trial (HCT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low calcium trial (LCT)
Number of subjects: 11
Study: 19682114

Group type: EXPERIMENTAL
Intervention: Yoga intervention (hour-long classes 3 days per week for 24 weeks)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (monthly luncheon and seminar, mailings)
Number of subjects: 118
Study: 17289744

Group type: EXPERIMENTAL
Intervention: Top quartile of systolic blood pressure (SBP) > 140 mmHg
Number of subjects: 7330

Group type: EXPERIMENTAL
Intervention: Mean systolic BP > or = 140 mmHg
Number of subjects: 7330

Group type: COMPARATOR
Intervention: Quartiles of blood pressure (BP)
Number of subjects: 7330
Study: 14984381

Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus amantadine (200 mg/day)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Interferon-alpha alone
Number of subjects: 181
Study: 11375883

Group type: EXPERIMENTAL
Intervention: Nirschl tennis elbow release with drilling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nirschl tennis elbow release without drilling
Number of subjects: 0
Study: 9207314

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitomycin/ifosfamide/cisplatin (MIC) regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin/etoposide (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive care plus cisplatin-based chemotherapy
Number of subjects: 0
Study: 7970447

Group type: EXPERIMENTAL
Intervention: Cardioscint non-imaging nuclear probe system
Number of subjects: 40
Study: 2442788

Group type: EXPERIMENTAL
Intervention: Reserpine 5 mg IM b.i.d. over 2 days (placebo-controlled, double-blind trial)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Desipramine (DMI) treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reserpine augmentation
Number of subjects: 8
Study: 31888783

Group type: EXPERIMENTAL
Intervention: Epinephrine rinse
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Diphenhydramine rinse
Number of subjects: 490

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 490
Study: 29486353

Group type: EXPERIMENTAL
Intervention: Antibiotic + indocyanine green + 810 nm wavelength diode laser (antimicrobial photodynamic therapy group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antibiotic alone (control group)
Number of subjects: 40
Study: 26836801

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment daily for two weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control without moxibustion
Number of subjects: 200
Study: 25260838

Group type: EXPERIMENTAL
Intervention: Pasireotide 40 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Pasireotide 60 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Active control (octreotide or lanreotide)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 198
Study: 23581697

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 240 mg/d
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 160 mg/d
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 80 mg/d, 160 mg/d, 240 mg/d
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 20082171

Group type: EXPERIMENTAL
Intervention: Telephone support intervention provided by trained senior peer counselors
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Training module and 20‐h course for senior peer counselors
Number of subjects: 107
Study: 18972728

Group type: EXPERIMENTAL
Intervention: Acupuncture plus exercise group (electroacupuncture and infrared ray radiation plus passive exercise)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise therapy group (active exercise after passive exercise)
Number of subjects: 60
Study: 15746683

Group type: EXPERIMENTAL
Intervention: Severe congenital anomalies and youngest gestational ages
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Maternal age (< 18 and > 34 years)
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Nontertiary hospital care
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Malpresentation
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Small for gestational age
Number of subjects: 1742

Group type: COMPARATOR
Intervention: Black race
Number of subjects: 1742

Group type: COMPARATOR
Intervention: Preeclampsia
Number of subjects: 1742
Study: 14671464

Group type: EXPERIMENTAL
Intervention: Electrocardiographic LVH present in 793 (8.3%) participants
Number of subjects: 9541

Group type: COMPARATOR
Intervention: No ECG-LVH
Number of subjects: 9541
Study: 10900676

Group type: EXPERIMENTAL
Intervention: Very low fat diet (diet I)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low fat diet (diet II)
Number of subjects: 37
Study: 8953350

Group type: EXPERIMENTAL
Intervention: Non-pharmacological nursing interventions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study: 1727097

Group type: EXPERIMENTAL
Intervention: Echocardiographic predictors (left ventricular dysfunction from 2-D echocardiograms)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Echocardiographic predictors (size of the left atrium from M-mode echocardiograms)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Echocardiographic results combined with clinical variables
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Echocardiographic results
Number of subjects: 568
Study: 6480875

Group type: EXPERIMENTAL
Intervention: 5 Gm standard activated charcoal every 2 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 Gm PX‐21 activated charcoal every 2 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 20 Gm standard activated charcoal every 2 hours
Number of subjects: 8
Study: 30938762

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 2432

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 2432

Group type: COMPARATOR
Intervention: Comparator (placebo or active comparator: sitagliptin 100 mg, exenatide extended release 2.0 mg)
Number of subjects: 2432
Study: 28424190

Group type: EXPERIMENTAL
Intervention: Inulin (30 g/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propionate (6 g/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cellulose (30 g/d)
Number of subjects: 16
Study: 25154757

Group type: EXPERIMENTAL
Intervention: Dipyrone (575 mg, three times a day for 72 hr)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Acetaminophen (500 mg, three times a day for 72 hr)
Number of subjects: 29
Study: 24107481

Group type: EXPERIMENTAL
Intervention: Docetaxel 40 mg/m² and cisplatin 40 mg/m² biweekly on days 1 and 15 every 4 weeks
Number of subjects: 48
Study: 21375777

Group type: EXPERIMENTAL
Intervention: Single-dose AmBisome® (7.5 mg/kg, escalating to 10, 12.5, and 15 mg/kg if ineffective)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Multi-dose AmBisome® (3 mg/kg/day on days 1-5, 14, and 21; total dose 21 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Single-dose AmBisome®
Number of subjects: 120

Group type: COMPARATOR
Intervention: Multi-dose AmBisome®
Number of subjects: 120
Study: 19533313

Group type: EXPERIMENTAL
Intervention: Active allergen immunotherapy (IT) with single insect extract (cockroach, housefly, or mosquito) and mixed allergen IT (two or three insect extracts)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 18603898

Group type: EXPERIMENTAL
Intervention: Misgav Ladach technique
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 400
Study: 14514933

Group type: EXPERIMENTAL
Intervention: Bradykinin (BK)
Number of subjects: 10

Group type: COMPARATOR
Intervention: L‐NMMA
Number of subjects: 10
Study: 10648310

Group type: EXPERIMENTAL
Intervention: Oral ketamine/midazolam
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intramuscular meperidine, promethazine, and chlorpromazine (DPT)
Number of subjects: 51
Study: 8862501

Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC, 2.5 mg po)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Arginine (ARG, 0.5 g/Kg iv in 30 min)
Number of subjects: 6
Study: 1738963

Group type: EXPERIMENTAL
Intervention: One-dose regimen of cefuroxime
Number of subjects: 2651

Group type: COMPARATOR
Intervention: Three-dose regimen of cefuroxime
Number of subjects: 2651
Study: 6469757

Group type: EXPERIMENTAL
Intervention: Misonidazole treatment
Number of subjects: 0
Study: 30487126

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 261
Study: 29587324

Group type: EXPERIMENTAL
Intervention: Nivolumab (Opdivo®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 27505315

Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK
Number of subjects: 68

Group type: COMPARATOR
Intervention: Wavefront-optimized PRK
Number of subjects: 68
Study: 24760847

Group type: EXPERIMENTAL
Intervention: BDNF Met(66) carriers
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Placebo administration
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Monetary gains
Number of subjects: 72
Study: 22149876

Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo plus exemestane
Number of subjects: 724
Study: 20551634

Group type: EXPERIMENTAL
Intervention: Intravaginal pentamycin 3, 10, 30, 60 or 100 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pentamycin vehicle
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravaginal pentamycin 60 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intravaginal pentamycin 100 mg
Number of subjects: 31
Study: 17402934

Group type: EXPERIMENTAL
Intervention: Human Patient Simulators (HPS) in addition to usual clinical training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual clinical training alone
Number of subjects: 12
Study: 15630048

Group type: EXPERIMENTAL
Intervention: Candesartan cilexitil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12394817

Group type: EXPERIMENTAL
Intervention: PnCV reconstituted in TETRAMUNE as a single injection in the right thigh (combined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PnCV in the left thigh and TETRAMUNE in the right thigh (separate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo reconstituted in TETRAMUNE in the right thigh (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined group (PnCV reconstituted in TETRAMUNE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separate group (PnCV and TETRAMUNE separately)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 10438983

Group type: EXPERIMENTAL
Intervention: Fresh blastocysts (cocultured or cultured in sequential media)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous conception
Number of subjects: 0
Study: 7763203

Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride (L-deprenyl)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha-tocopherol)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 800
Study: 2272092

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 86677

Group type: EXPERIMENTAL
Intervention: Infants discharged when clinically well and after passing the nadir of postnatal weight-loss.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Infants discharged at a traditional weight of 2200 g.
Number of subjects: 40
Study: 31595499

Group type: EXPERIMENTAL
Intervention: Dupilumab 2 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dupilumab 4 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dupilumab (both doses)
Number of subjects: 40
Study: 30292541

Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF) treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 67
Study: 27765690

Group type: EXPERIMENTAL
Intervention: Animal Protein Diet (AP); rich in meat and dairy foods
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Plant Protein Diet (PP); mainly legume protein
Number of subjects: 37
Study: 25800457

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once‐monthly injectable antipsychotic (PP1M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate monotherapy (PP1M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate adjunctive therapy (PP1M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22889586

Group type: EXPERIMENTAL
Intervention: 24IU intranasal oxytocin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 48IU intranasal oxytocin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 20657311

Group type: EXPERIMENTAL
Intervention: Exercise 1 (E1: 20 minutes, 1 lap in the circuit)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise 2 (E2: 40 minutes, 2 laps in the circuit)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (C: 40 minutes of rest)
Number of subjects: 16
Study: 19448386

Group type: EXPERIMENTAL
Intervention: Nutrition and exercise strategies
Number of subjects: 62

Group type: COMPARATOR
Intervention: Staff compliance
Number of subjects: 62
Study: 16733169

Group type: EXPERIMENTAL
Intervention: Cell-saver processed suction blood (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cell-saver unprocessed suction blood (n = 12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation with tumor necrosis factor alpha concentration
Number of subjects: 25
Study: 11901581

Group type: EXPERIMENTAL
Intervention: 80 gauge mini brackets
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 80 gauge standard brackets
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 gauge mini brackets
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 gauge standard brackets
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between 80 and 100 gauge mini and standard size brackets
Number of subjects: 80

Group type: COMPARATOR
Intervention: Brackets of the same surface area with different gauge mesh size
Number of subjects: 80
Study: 10421835

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 98
Study: 7495111

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg once daily
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study: 2268518

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate tablets at a dose of 1 g twice daily
Number of subjects: 619

Group type: COMPARATOR
Intervention: Ciprofloxacin tablets 500 mg twice daily
Number of subjects: 619
Study: 298342

Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 20 mg naloxone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26